These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25792249)

  • 1. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
    Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.
    Perri T; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
    Fertil Steril; 2021 Aug; 116(2):538-545. PubMed ID: 33823990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gronwald J; Glass K; Rosen B; Karlan B; Tung N; Neuhausen SL; Moller P; Ainsworth P; Sun P; Narod SA; Lubinski J; Kotsopoulos J;
    Fertil Steril; 2016 Mar; 105(3):781-785. PubMed ID: 26698676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Lavie O; Chetrit A; Novikov I; Sadetzki S;
    Gynecol Oncol; 2019 May; 153(2):320-325. PubMed ID: 30872026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
    Shapira M; Raanani H; Feldman B; Srebnik N; Dereck-Haim S; Manela D; Brenghausen M; Geva-Lerner L; Friedman E; Levi-Lahad E; Goldberg D; Perri T; Eldar-Geva T; Meirow D
    Fertil Steril; 2015 Nov; 104(5):1162-7. PubMed ID: 26335130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
    Laitman Y; Michaelson-Cohen R; Levi E; Chen-Shtoyerman R; Reish O; Josefsberg Ben-Yehoshua S; Bernstein-Molho R; Keinan-Boker L; Rosengarten O; Silverman BG; Perri T; Korach J; Mor P; Ephrat Ben-Baruch N; Levy Lahad E; Friedman E;
    Cancer; 2019 Mar; 125(5):698-703. PubMed ID: 30489631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
    Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
    Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
    Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
    J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimüllerian hormone levels are lower in BRCA2 mutation carriers.
    Johnson L; Sammel MD; Domchek S; Schanne A; Prewitt M; Gracia C
    Fertil Steril; 2017 May; 107(5):1256-1265.e6. PubMed ID: 28476184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
    Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.